Literature DB >> 16684940

Symptoms of posttraumatic stress disorder in patients who have had a myocardial infarction.

Eyal Shemesh1, Maya Koren-Michowitz, Rachel Yehuda, Olga Milo-Cotter, Elmer Murdock, Zvi Vered, Benjamin L Shneider, Jack M Gorman, Gad Cotter.   

Abstract

Symptoms of posttraumatic stress disorder (PTSD) and risk factors for recurrent ischemia were evaluated in 65 survivors of a myocardial infarction (MI) at baseline and 6 months afterward. PTSD patients had more uncontrolled cardiovascular risk factors at baseline. Patients with PTSD (N=14) were offered trauma-focused cognitive-behavior treatment (CBT) plus a nonspecific intervention to improve adherence to medical recommendations. Adherence to aspirin improved in recipients of the nonspecific intervention (N=8); PTSD symptoms and cardiovascular risk improved in patients who received CBT (N=6). PTSD may be a treatable risk factor for poor post-MI outcome. Further research is needed to evaluate treatment options.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684940     DOI: 10.1176/appi.psy.47.3.231

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  21 in total

1.  Spiritual reconfigurations of self after a myocardial infarction: Influence of culture and place.

Authors:  Danielle Groleau; Rob Whitley; François Lespérance; Laurence J Kirmayer
Journal:  Health Place       Date:  2010-04-24       Impact factor: 4.078

2.  The Effectiveness of Medication Adherence Interventions Among Patients With Coronary Artery Disease: A Meta-analysis.

Authors:  Jo-Ana D Chase; Jennifer L Bogener; Todd M Ruppar; Vicki S Conn
Journal:  J Cardiovasc Nurs       Date:  2016 Jul-Aug       Impact factor: 2.083

3.  [Posttraumatic stress disorder : Trigger and consequence of vascular diseases].

Authors:  J Schöner; G Kronenberg; A Heinz; M Endres; K Gertz
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

4.  Posttraumatic stress disorder due to acute cardiac events and aversive cognitions towards cardiovascular medications.

Authors:  S Ali Husain; Donald Edmondson; Marin Kautz; Redeana Umland; Ian M Kronish
Journal:  J Behav Med       Date:  2017-12-04

5.  Does Illness Perception Predict Posttraumatic Stress Disorder in Patients with Myocardial Infarction?

Authors:  Serap Oflaz; Şahika Yüksel; Fatma Şen; Filiz Özdemiroğlu; Ramazan Kurt; Hüseyin Oflaz; Erdem Kaşikcioğlu
Journal:  Noro Psikiyatr Ars       Date:  2014-06-01       Impact factor: 1.339

6.  Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks.

Authors:  Ian M Kronish; Donald Edmondson; Judith Z Goldfinger; Kezhen Fei; Carol R Horowitz
Journal:  Stroke       Date:  2012-05-22       Impact factor: 7.914

7.  Posttraumatic stress due to an acute coronary syndrome increases risk of 42-month major adverse cardiac events and all-cause mortality.

Authors:  Donald Edmondson; Nina Rieckmann; Jonathan A Shaffer; Joseph E Schwartz; Matthew M Burg; Karina W Davidson; Lynn Clemow; Daichi Shimbo; Ian M Kronish
Journal:  J Psychiatr Res       Date:  2011-07-31       Impact factor: 4.791

Review 8.  PTSD in solid organ transplant recipients: Current understanding and future implications.

Authors:  C Supelana; R A Annunziato; D Kaplan; J Helcer; M L Stuber; E Shemesh
Journal:  Pediatr Transplant       Date:  2015-12-09

9.  Changes in plasma lipid concentrations and risk of coronary artery disease in army veterans suffering from chronic posttraumatic stress disorder.

Authors:  Alma Dzubur Kulenović; Abdulah Kucukalić; Daniel Malec
Journal:  Croat Med J       Date:  2008-08       Impact factor: 1.351

10.  Interventions for posttraumatic stress disorder symptoms induced by medical events: A systematic review.

Authors:  Mytra Haerizadeh; Jennifer A Sumner; Jeffrey L Birk; Christopher Gonzalez; Reuben Heyman-Kantor; Louise Falzon; Liliya Gershengoren; Peter Shapiro; Ian M Kronish
Journal:  J Psychosom Res       Date:  2019-12-19       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.